| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
The present study yielded a new mechanism for endothelial barrier dysfunction. By using an animal model of pulmonary hypertension, a thrombin receptor antagonist was found to effectively prevent the development of pulmonary hypertension and prolonged the survival. The contractile responsiveness of pulmonary artery was found to be enhanced in pulmonary hypretension. As a result, thrombin receptor antagonist is suggested to be potentially useful as a new strategy for treatment of pulmonary hypertension. Proposals of Japanese and international patent for the invention of new treatment for pulmonary hypertension has been submitted.
|
